• Intellia Therapeutics (NasdaqGM:NTLA) plans to announce topline results from the first Phase 3 trial of an in vivo CRISPR gene editing candidate for hereditary angioedema.
• The upcoming readout will be the first-ever Phase 3 data release for an in vivo CRISPR therapy.
• The results are expected to be highly relevant for Intellia's future plans and for gene editing drug development more broadly.

Intellia Therapeutics, trading at around $13.63, sits at the center of attention as it approaches a Phase 3 milestone that many in biotech have been watching for years. The stock has seen a 48.0% return year to date and a 64.0% return over the past year, while its 3 year and 5 year returns of 63.9% and 82.2% respectively highlight how volatile sentiment around gene editing can be. This mix of strong recent performance and weaker longer term returns helps frame the stakes around the coming data.

For investors following gene editing, the upcoming hereditary angioedema readout is about more than one asset or one company. As the first Phase 3 in vivo CRISPR trial to reach a topline result, it could influence how regulators, partners, and competitors think about similar programs and the pace at which they advance late stage studies.

Stay updated on the most important news stories for Intellia Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Intellia Therapeutics.

The HAELO Phase 3 readout for lonvoguran ziclumeran is important for Intellia because it brings the company to the threshold of having a potential first commercial product and a real-world test of its in vivo CRISPR platform. Hereditary angioedema is a rare disease but current treatments are chronic and often costly, so a one-time gene editing approach speaks directly to payer and patient interest in reducing long-term treatment burden. For Intellia, positive data could support a move from being valued largely on pipeline expectations to being assessed on a defined product opportunity, including potential future pricing discussions and partnering interest. The readout also matters for the wider gene editing space, where peers like CRISPR Therapeutics and Editas Medicine are working with different modalities and indications, and investors compare safety, durability and practicality across platforms.

How This Fits Into The Intellia Therapeutics Narrative

• The upcoming lonvoguran Phase 3 data directly ties into the narrative that late-stage readouts can support earlier commercialization for Intellia's in vivo CRISPR programs and build real-world validation for the platform.
• The narrative highlights concentration risk around a small number of lead programs, and this HAE trial is a clear example, as any safety or efficacy concerns could challenge assumptions about long-term revenue potential from hereditary angioedema.
• The broader narrative focuses heavily on ATTR programs and financial discipline, while this first-in-class HAE Phase 3 readout may not be fully reflected in how investors think about the balance between diversification of indications and execution risk.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Intellia Therapeutics to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Intellia is still loss making and analysts do not expect profitability over the next 3 years, so progress on HAELO does not remove funding and cash burn risk.
• ⚠️ The share price has been volatile over the past 3 months compared to the US market, and a first-in-human technology at Phase 3 can see sharp reactions to any perceived safety, durability or regulatory concerns.
• 🎁 Analysts expect very large revenue growth over the next few years, and a successful HAE product could provide an important proof point for those expectations.
• 🎁 The shares are assessed as trading at a large discount to one estimate of fair value, and a clear clinical success in hereditary angioedema is one of the key events that could influence how investors think about that gap.

What To Watch Going Forward

After the topline HAELO readout, pay close attention to three things: the magnitude and consistency of attack reduction, the safety profile compared with chronic hereditary angioedema drugs from companies such as Takeda and CSL, and any early commentary on regulatory interactions or filing plans. The webcast on April 27, 2026 will also be worth watching for management detail on how lonvoguran could fit in real-world treatment pathways and how HAELO data might inform other in vivo CRISPR programs, including ATTR. Market reaction around the event may be sharp in either direction, so it can help to focus on whether the results change the long-term thesis rather than just the short-term price move.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Intellia Therapeutics, head to the community page for Intellia Therapeutics to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.